author-photo

Bruce E. Strober

University of Connecticut
New York University
University of Connecticut Health Center

239

Papers

10156

Citations

Citation Trend

Filter By

Papers (239) Sort By

Journal Conference Others

27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Phosphodiesterase-4 and Janus Kinase Inhibitors

2021
- Gillian K. Weston
- Bruce E. Strober
Show All
- Source
- Cite
- Save
Citations (0)
26698 Characteristics and disease burden in patients with mild to moderate vs severe plaque psoriasis in real-world settings: Results from the Corrona Psoriasis Registry

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Bimekizumab versus Secukinumab in Plaque Psoriasis.

2021 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (15)
25602 Improvements and response achievement in PASI subscale domains for head scaling and erythema in apremilast-treated patients with moderate to severe plaque psoriasis of the scalp: Results from the STYLE study

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
25665 Efficacy and safety of mirikizumab in psoriasis: 52-week results from the OASIS-1 randomized controlled trial

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)